Leerink Partners made a slight adjustment to the price target of Inspire Medical Systems (NYSE:INSP), raising it from $193.00 to $194.00, while keeping a Market Perform rating on the stock. According ...

CVS Health investors will closely examine this week turnaround initiatives spearheaded by new CEO David Joyner and their ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Labcorp Holdings (LH – Research Report) and ...

Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Tango Therapeutics in a ...

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

Leerink raised the firm’s price target on Axsome Therapeutics (AXSM) to $150 from $110 and keeps an Outperform rating on the shares. The ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...